Key Partnerships

Kymera Therapeutics has strategically formed key partnerships to leverage expertise, resources, and capabilities essential for advancing drug discovery and development. These partnerships include:

• Collaboration with biopharmaceutical companies: Kymera Therapeutics collaborates with established biopharmaceutical companies to access their experience in drug development, regulatory expertise, and commercial capabilities. These collaborations enable Kymera to accelerate the translation of their discoveries into novel therapies.
• Research institutions for drug discovery: By partnering with leading research institutions, Kymera gains access to cutting-edge scientific knowledge and technologies that drive the discovery of novel degrader therapies. These collaborations foster innovation and provide a strong foundation for the development of new treatment modalities.
• Contract research organizations (CROs) for clinical trials: Kymera collaborates with CROs to conduct clinical trials efficiently and effectively. By leveraging the expertise and infrastructure of CROs, Kymera ensures the successful execution of clinical studies to demonstrate the safety and efficacy of their degrader therapies.
• Licensing agreements for technology platforms: Kymera enters into licensing agreements to access cutting-edge technologies and platforms that enhance their drug discovery capabilities. By partnering with technology providers, Kymera can leverage advanced tools and resources to accelerate the identification and optimization of novel degrader molecules.

Key Activities

Kymera Therapeutics is focused on research and development in targeted protein degradation, a novel approach to drug discovery that has the potential to address a wide range of diseases. Our key activities in this area include:

• Research and development in targeted protein degradation: We are constantly exploring new ways to leverage the body's natural protein degradation mechanisms to develop therapeutics that target specific disease-causing proteins. This involves a combination of in vitro and in vivo studies to identify and validate potential drug targets.
• Clinical trial management: Once we have identified a promising candidate, we work on conducting clinical trials to evaluate its safety and efficacy in patients. This involves designing and implementing clinical trial protocols, recruiting patients, and analyzing the data to determine the drug's effectiveness.
• Pipeline development for new therapies: We are always looking to expand our pipeline of therapies by identifying new drug targets and developing novel compounds. This involves a combination of internal research and strategic collaborations with academic institutions and other industry partners.
• Collaboration on research projects: We believe in the power of collaboration and regularly partner with leading academic researchers and other industry players to advance the field of targeted protein degradation. These collaborations help us access new technologies, expertise, and resources that can accelerate our drug discovery efforts.

Overall, our key activities are aimed at advancing the science of targeted protein degradation and developing innovative therapies that have the potential to transform the treatment of a wide range of diseases.

Key Resources

Expertise in biochemistry and molecular biology: Kymera Therapeutics boasts a team of experts in biochemistry and molecular biology that are at the forefront of developing novel therapies targeting previously undruggable proteins. These individuals bring a wealth of knowledge and experience to the company, allowing for groundbreaking research and drug discovery.

Proprietary technology platforms for drug discovery: Kymera Therapeutics has developed cutting-edge technology platforms that enable the identification of new drug targets and the design of small molecule degraders to effectively degrade these targets. These platforms give Kymera a competitive edge in the field of targeted protein degradation.

Research laboratories and facilities: Kymera Therapeutics has state-of-the-art research laboratories and facilities equipped with the latest technology and instrumentation for drug discovery and development. These facilities support the company's research efforts and allow for the efficient testing and optimization of novel therapies.

Intellectual property on novel therapies: Kymera Therapeutics holds a strong portfolio of intellectual property on its novel therapies, providing protection for its proprietary technologies and drug candidates. This intellectual property gives Kymera a competitive advantage in the market and ensures the long-term value of its research and development efforts.

Value Propositions

At Kymera Therapeutics, our value propositions focus on providing innovative solutions for previously undruggable targets in various diseases. Our targeted protein degradation technology allows for precise therapies, potentially reducing side effects compared to traditional treatments. We are committed to addressing unmet medical needs and improving patient outcomes.

• Our approach to targeted protein degradation opens up new possibilities for treating diseases that were previously considered undruggable.
• We utilize small molecules to selectively remove disease-causing proteins, offering a novel approach to therapy.

• By targeting specific proteins for degradation, we can tailor treatment to each patient's unique disease profile.
• This precision allows for more effective therapies with potentially fewer side effects compared to broad-acting treatments.

• Our focus on targeted protein degradation aims to minimize off-target effects, reducing the risk of adverse reactions.
• By selectively removing disease-causing proteins, we can potentially achieve better treatment outcomes with fewer side effects.

• We prioritize developing therapies for diseases with limited treatment options, where our approach can make a significant impact.
• Our dedication to improving patient outcomes drives our efforts to address unmet medical needs across a range of diseases.

Customer Relationships

At Kymera Therapeutics, we prioritize strong relationships with our customers to ensure we are meeting their needs and providing value at every stage of our drug development process. Our customer relationships are built on:

• Engagement through scientific communities and forums: We actively participate in scientific communities and forums to stay connected with key opinion leaders, academic researchers, and industry experts. By engaging in these spaces, we are able to exchange knowledge, share insights, and gather feedback on our research and development efforts.
• Collaboration with healthcare professionals and researchers: We work closely with healthcare professionals and researchers to better understand the needs of patients and to ensure that our drug candidates are being developed in alignment with the latest scientific advancements. By collaborating with experts in the field, we are able to leverage their expertise and knowledge to drive our drug development efforts forward.
• Support and partnerships with patient advocacy groups: We partner with patient advocacy groups to gain insights into the patient experience, understand unmet medical needs, and ensure that our drug candidates are addressing real-world challenges. By working closely with patient advocacy groups, we are able to incorporate patient perspectives into our research and development efforts and ensure that our therapies are patient-centric.
• Transparency and communication in clinical trial updates: We are committed to transparency and open communication with all stakeholders, including patients, healthcare professionals, researchers, and investors. We provide regular updates on our clinical trial progress, results, and milestones to ensure that everyone is informed and engaged in our drug development journey. By maintaining open lines of communication, we are able to build trust with our customers and demonstrate our commitment to advancing innovative therapies.

Channels

As a biopharmaceutical company specializing in targeted protein degradation, Kymera Therapeutics utilizes a variety of channels to reach its key stakeholders and achieve its strategic goals.

Professional medical conferences and journals: Kymera actively participates in and presents at professional medical conferences and publishes in reputable journals to showcase its latest research, findings, and advancements in the field of targeted protein degradation. By engaging with key opinion leaders and experts in the industry, Kymera can build credibility and visibility for its innovative approach to drug development.

Company's own website and digital platforms: Kymera's website serves as a central hub for information about the company, its pipeline, technology platform, and upcoming events. Through digital marketing and social media channels, Kymera can reach a broader audience, including investors, potential partners, and patients interested in its research and development efforts.

Collaborations and partnerships with healthcare institutions: Kymera forms strategic collaborations and partnerships with healthcare institutions, research organizations, and academic centers to leverage expertise, resources, and capabilities. By working closely with these partners, Kymera can accelerate the development and commercialization of its novel therapies and expand its reach in the healthcare ecosystem.

Direct engagement with regulatory authorities: Kymera maintains direct engagement with regulatory authorities, such as the FDA and EMA, to ensure compliance with regulations and guidance throughout the drug development process. By collaborating with regulators early on, Kymera can address potential issues proactively, streamline the regulatory approval process, and bring its therapies to market efficiently.

Customer Segments

The primary customer segments for Kymera Therapeutics include:

• Pharmaceutical companies: These companies are looking for advanced drug development platforms to support their drug discovery efforts. Kymera's innovative approach to targeted protein degradation could provide them with new opportunities to create novel therapeutics.
• Academic and research institutions: Institutions in the life sciences field may be interested in collaborating with Kymera to further explore the potential of targeted protein degradation. Kymera's platform could help these institutions accelerate their research and development efforts.
• Healthcare providers: Healthcare providers are always seeking new and effective treatments for various diseases. Kymera's novel approach could offer them new options for patients with conditions that currently lack effective therapies.
• Patients: Ultimately, patients with diseases that have limited treatment options are a key customer segment for Kymera. By developing new therapeutics through targeted protein degradation, Kymera aims to provide hope and improved outcomes for these patients.

Cost Structure

High R&D expenses for drug discovery and development: Kymera Therapeutics invests a significant amount of resources into research and development in order to discover and develop novel therapies targeted at previously undruggable diseases. These expenses cover the costs associated with the early stages of drug discovery, such as target identification and validation, as well as the preclinical and clinical development phases.

Costs associated with conducting clinical trials: Conducting clinical trials is a crucial component of bringing a new therapy to market. Kymera Therapeutics incurs expenses related to patient recruitment, study monitoring, data collection and analysis, as well as regulatory compliance throughout the various phases of clinical development.

Investment in technology and intellectual property: To support its drug discovery efforts, Kymera Therapeutics invests in cutting-edge technology and tools that enable the identification and validation of novel targets. Additionally, the company places a high value on intellectual property protection to safeguard its innovative therapeutic approaches.

Operating expenses for staff, facilities, and equipment: Kymera Therapeutics must cover the costs associated with maintaining a team of skilled scientists and researchers, as well as operating facilities equipped with state-of-the-art equipment for drug discovery and development. These operational expenses also include overhead costs such as utilities, maintenance, and other necessary support services.

Revenue Streams

Licensing fees from technology and drug patents: Kymera Therapeutics generates revenue through licensing its innovative technologies and drug patents to other pharmaceutical companies. These fees are negotiated as part of partnerships and collaborations, providing a steady stream of income for the company.

Partnership and collaboration agreements: Kymera Therapeutics forms strategic partnerships and collaborations with other companies in the pharmaceutical industry. These agreements often involve joint research and development efforts, sharing of resources, and co-promotion of products. In return, Kymera receives financial compensation and royalties, further diversifying its revenue streams.

Sales of developed drugs upon market approval: One of the primary revenue streams for Kymera Therapeutics is the sale of drugs that have been developed and approved by regulatory agencies. Once these drugs are on the market, Kymera can earn revenue through sales to patients, healthcare providers, and distributors.

Grants and funding from research institutions: Kymera Therapeutics also receives revenue in the form of grants and funding from research institutions, government agencies, and non-profit organizations. These funds support the company's research and development efforts, allowing Kymera to advance its pipeline of therapeutic candidates.